ArticleCanadian respiratory journal2026
Potential Impact of Biologic Use on Asthma-Related Hospitalization: An Epidemiological Study in Hong Kong.
Article in Canadian respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potential Impact of Biologic Use on Asthma-Related Hospitalization: An Epidemiological Study in Hong Kong.Canadian respiratory journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundWhile the individual effects of biologics in asthma are well demonstrated, the potential impact of the use of biologics on overall asthma-related hospitalization at a population-based level has not been reported.
methodsA territory-wide study conducted in Hong Kong, involving all adult patients with asthma managed in Hospital Authority. The primary outcome was the change in asthma-related hospitalization from 2014 to 2023, correlating with the number of biologic use among patients with asthma and adjusted for Air Quality Health Index and influenza case number.
resultsThe weekly asthma-related hospitalization was 96 episodes at the start of the study period and 78 episodes at the end of the study period. There was a significant reduction of asthma-related hospitalization associated with biologic usage, giving the estimated risk ratio of 0.994 (95% CI = 0.991-0.996, p value < 0.05). The estimated break-point for the change in asthma-related hospitalization was at Week 169 (95% CI = 130.3-207.7), which was the week of 19/3/2017 to 25/3/2017. The slopes before and after the break-point were 0.022 and -0.191 with the difference in the two slope estimates being significant (p < 0.001) according to the Davies test. The significant difference in the slope before and after the break-point suggested that beyond Week 169, there was a trend of significant reduction in asthma-related hospitalization.
conclusionWe observed a reduction in asthma-related hospitalizations throughout the study period with a potential temporal association with the increase in biologic prescription. While biologics provided benefits in individual level, the possible benefits in a population-based level could be related to a more comprehensive care in severe asthma patients from the introduction of biologics for severe asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.